Log In
BCIQ
Print this Print this
 

CT-179

  Manage Alerts
Collapse Summary General Information
Company Curtana Pharmaceuticals Inc.
DescriptionSmall molecule inhibitor of oligodendrocyte transcription factor 2 (OLIG2)
Molecular Target Oligodendrocyte transcription factor 2 (OLIG2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma multiforme (GBM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today